A board departure at genedrive headlined a busy day for small-cap healthcare names, with the point-of-care diagnostics company disclosing the exit of its chairman as a wider governance rebuild gets underway. Elsewhere, Physiomics made a senior internal promotion, and EMV Capital reported fresh equity raises at two of its portfolio companies.
Genedrive chairman departs as board recruitment opens
genedrive (AIM:GDR) announced the departure of chairman Dr Ian Gilham from its board, with the pharmacogenetic testing company now searching for a new independent Non-Executive Chairman alongside two additional non-executive directors. The announcement extended a period of board transition at the company, whose shares fell 3.06% to 1.2602p on the news.
Genedrive focuses on rapid, point-of-care pharmacogenetic testing and has been reshaping its leadership structure. The search for three board-level appointments signals a substantive governance overhaul rather than a routine succession, with outgoing directors Gino Miele and Chris Yates also part of the broader picture as the company works to reconstitute its non-executive bench.
Physiomics elevates Head of Biometrics to COO
Physiomics (AIM:PYC), the AIM-listed computational modelling company, promoted Jesse Thissen from Head of Biometrics to Chief Operating Officer as it looks to build operational capacity alongside commercial growth. The appointment is an internal step-up rather than an external hire, reflecting the company's intent to scale from within. Shares were unchanged at 0.475p.
EMV Capital portfolio companies Glycotest and ProAxsis secure independent funding
EMV Capital (AIM:EMVC) reported that two of its portfolio companies, Glycotest and ProAxsis, have completed fresh equity fundraisings, marking what CEO Dr Ilian Iliev described as their transition from incubation to independently funded growth companies. The milestone is significant for EMV Capital's model, which backs early-stage life science and deep technology businesses through to the point where they can attract outside capital on their own terms. Shares in EMV Capital edged up 0.97% to 52.0p.
